September 2014 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2013/14 Invitation to Tender, dated 07 November 2013.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
AMENDMENT to July 2014 tender notification: in bold and strikethrough
Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current pack price | New pack price | Hospital Supply Brand (Supplier) | DV limit | Date of listing/price change for tender winning brand | Hospital Supply Status date (and delisting of other listed brands) | Brand (Supplier) to be delisted |
|---|---|---|---|---|---|---|---|---|
| Docetaxel | Inj 20 mg; 1 vial | $48.75 | $13.70 | DBL Docetaxel (Hospira) |
1% | 1 October 2014 | 1 December 2014 | Docetaxel Sandoz (Novartis) |
| Docetaxel | Inj 80 mg; 1 vial | $195.00 | $29.99 | DBL Docetaxel (Hospira) |
1% | 1 October 2014 | 1 December 2014 | Docetaxel Sandoz (Novartis) |
|
DBL Docetaxel will be listed in Section B of the Pharmaceutical Schedule (as PCT only – Specialist) from 1 October 2014 at the prices above. The price and subsidy of docetaxel (PCT only – Retail Pharmacy Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 October 2014. The subsidy for docetaxel inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from $2.63 per 1 mg to $0.61 per 1 mg from 1 October 2014 1 December 2014. |
||||||||
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to currently listed pharmaceuticals where only the current brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current pack price | New pack price | Sole supply brand (Supplier) | Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
| Bisoprolol fumarate | Tab 2.5 mg; 30 tablets, blister pack |
$3.88 | $2.40 | Bosvate (Douglas) |
1 January 2015 | 1 April 2015 |
| Bisoprolol fumarate | Tab 5 mg; 30 tablets, blister pack |
$4.74 | $3.50 | Bosvate (Douglas) |
1 January 2015 | 1 April 2015 |
| Bisoprolol fumarate | Tab 10 mg; 30 tablets, blister pack |
$9.18 | $6.40 | Bosvate (Douglas) |
1 January 2015 | 1 April 2015 |
| Omeprazole | Cap 10 mg; 90 capsules, bottle |
$2.91 | $2.23 | Omezol Relief (Mylan) |
1 November 2014 | 1 February 2015 |
| Omeprazole | Cap 20 mg; 90 capsules, bottle |
$3.78 | $2.91 | Omezol Relief (Mylan) |
1 November 2014 | 1 February 2015 |
| Omeprazole | Cap 40 mg; 90 capsules, bottle |
$5.57 | $4.42 | Omezol Relief (Mylan) |
1 November 2014 | 1 February 2015 |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current pack price | New pack price | Hospital Supply Brand (Supplier) | DV limit | Date of listing/price change for tender winning brand | Hospital Supply Status date (and delisting of other listed brands) | Brand (Supplier) to be delisted |
|---|---|---|---|---|---|---|---|---|
| Metronidazole | Inj 5 mg per ml; 100 ml bag |
$12.30 | $6.94 | Metronidazole-AFT (AFT) |
1% | 1 February 2015 | 1 April 2015 | Metronidazole Baxter (Baxter) |
Tenders awarded to listed pharmaceuticals where only the current brand is listed.
The decisions were as follows:
| Chemical Name | Presentation;Pack size and type | Current pack price | New pack price | Hospital Supply Brand (Supplier) | DVLimit | Date of price change | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
| Bisoprolol fumarate | Tab 2.5 mg; 30 tablets, blister pack |
$3.88 | $2.40 | Bosvate (Douglas) |
1% | 1 January 2015 | 1 March 2015 |
| Bisoprolol fumarate | Tab 5 mg; 30 tablets, blister pack |
$4.74 | $3.50 | Bosvate (Douglas) |
1% | 1 January 2015 | 1 March 2015 |
| Bisoprolol fumarate | Tab 10 mg; 30 tablets, blister pack |
$9.18 | $6.40 | Bosvate (Douglas) |
1% | 1 January 2015 | 1 March2015 |
| Omeprazole | Cap 10 mg; 90 capsules, bottle |
$2.91 | $2.23 | Omezol Relief (Mylan) |
1% | 1 November 2014 | 1 January 2015 |
| Omeprazole | Cap 20 mg; 90 capsules, bottle |
$3.78 | $2.91 | Omezol Relief (Mylan) |
1% | 1 November 2014 | 1 January 2015 |
| Omeprazole | Cap 40 mg; 90 capsules, bottle |
$5.57 | $4.42 | Omezol Relief (Mylan) |
1% | 1 November 2014 | 1 January 2015 |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2012/13 Invitation to Tender, dated 31 October 2012 and 2013/14 Invitation to Tender, dated 07 November 2013:
2012/13 Invitation to Tender
| Chemical Name | Line Item |
|---|---|
| Phenoxymethylpenicillin (Penicillin V) |
Cap 250 mg |
| Phenoxymethylpenicillin (Penicillin V) |
Cap 500 mg |
| Tranexamic Acid | Inj 100 mg per ml, 5 ml – 10 ml |
| Ziprasidone | Cap 20 mg |
| Ziprasidone | Cap 40 mg |
| Ziprasidone | Cap 60 mg |
| Ziprasidone | Cap 80 mg |
2013/14 Invitation to Tender
| Chemical Name | Line Item |
|---|---|
| Artesunate | Inj 60 mg |
| Celecoxib | Cap 100 mg |
| Celecoxib | Cap 200 mg |
| Cidofovir | Inj 75 mg per ml, 5 ml |
| Clofazimine | Cap 50 mg |
| Clonazepam | Tab 500 mcg |
| Clonazepam | Tab 2 mg |
| Cyclophosphamide | Inj 1 g |
| Cyclophosphamide | Inj 2 g |
| Cyclophosphamide | Tab 50 mg |
| Esomeprazole | Inj 40 mg |
| Etoricoxib | Tab 60 mg |
| Etoricoxib | Tab 90 mg |
| Etoricoxib | Tab 120 mg |
| Mebendazole | Tab 100 mg |
| Mefenamic acid | Cap 250 mg |
| Meloxicam | Tab 7.5 mg |
| Nitazoxanide | Oral liquid 100 mg per 5 ml |
| Spiramycin | Tab 500 mg |
| Tobramycin | Inj 40 mg per ml, 2 ml |
For products included in the 2012/13 or the 2013/14 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.